Tissue polypeptide specific antigen (TPS) measures an antigenic determinant associated with human cytokeratin t8. TPS is a marker of tumor cell activity in contrast to markers related to tumor burden. The value of detecting circulating TP8 lies in the early detection of recurrence by serial determinations and in the rapid assessment of the efficacy of the treatment. Pretreatment levels of TPS in patients with metastatic breast cancer are related with prognosis. Decreasing TPS levels during therapy monitoring indicate response and a fast response is correlated to favourable prognosis. Increasing TPS levels, in the presence of clinically stable disease or partial remission, predict disease progression with a considerable lead-time. Improved effectiveness in breast cancer management can be seen when TPS is used in combination with CA 15-3. When tumor marker determinations are applied in a proper way in the appropriate situation, the results can assist the oncologist. Thus monitoring of therapy in patients with metastatic breast cancer should be based upon serial TP8 and CA 15-3 determinations in serum. The use of tumor marker determinations in the early follow-up interval following surgery to detect early tumor recurrence may be simpler, more sensitive and less expensive than imaging methods.
, but this has not been confirmed in other studies (14) . Of special note was the fact that serum levels of CA 15-3 and CEA in stage III disease were not considerably higher than in patients with early breast cancer (stages I and II) (14) . The same controversy has also been reported for TPS, as only slightly higher levels were present with stage III patients compared with stage II patients (14) . The sensitivity of TPS in primary breast cancer has been reported to be between 30-40% (14, 15) , demonstating the similar sensitivity as for CA 15-3 and CEA. These tumor markers are only of limited value in the diagnosis of primary breast cancer and none of the serum tumor markers studied proved to be a significant predictor of breast cancer (12) (13) (14) (15) (16) . However, it is still not accepted to initiate or change treatment based solely upon increasing tumor marker levels (treatment failures).
TPS in metastatic breast cancer
The development of metastatic breast cancer creates a situation where only pallitive treatment of the patients are possible. CEA and CA t 5-3 have been the marker of choice during the last ten years to monitor patients with metastatic breast cancer (13, 20) . Several groups reported the advantage of using TPS in combination with CA 15-3 to monitor metastatic breast cancer (15, (21) (22) (23) (24) . TPS was elevated more often than CA 
